Strategic partnerships Gemphire has a history of out-licensing and partnerships (Beijing SL Pharmaceutical, Pfizer asset acquisitions, and a merger with NeuroBo) that demonstrate openness to collaboration and potential for distribution, co-development, or licensing deals in multiple regions, including China.

Orphan and rare disease focus The lead candidate gemcabene targets orphan indications like HoFH and broader dyslipidemia segments, suggesting BD opportunities with specialty cardiology and rare disease clinics, KOL networks, and reimbursement pathways for high-need patients.

Global market access Past US public listings and overseas licensing activity indicate a push for international commercialization; leverage existing relationships to explore regional launches, strategic investments, or co-promotion agreements in Asia and other markets.

Clinical-stage collaboration Gemphire’s plan to initiate late-stage trials within a defined window signals readiness for collaboration on pivotal studies, including CRO partnerships, investigator-initiated trials, or strategic funding arrangements to accelerate development.

Regulatory and data readiness With a focus on dyslipidemia and potential NASH/NAFLD indications, there are opportunities to propose regulatory consults, biomarker-driven patient recruitment programs, and priced trial designs aligned with payer expectations and outcomes data.